Rituximab biosimilar approved in Latin America

Biosimilar News

On June 6, 2017, Biocad, a Russia biotechnology company, announced that it has obtained marketing authorization for its rituximab biosimilar in Bolivia and Honduras under the trade name USMAL, and that shipments will start in the beginning of Q3 2017.  Biocad further stated that it is registering its rituximab biosimilar in other countries in the region and expects to receive two more marketing authorization certificates by the end of 2017.

Download PDF

Tagged with 

Comments are closed.